Lu177 PSMA Radioligand Therapy: In vivo SPECT/CT quantitation

被引：0
|
作者：
Keidar, Zohar [1 ]
Lugassil, Rachel [1 ]
Raysberg, Elyahu [1 ]
Frenkel, Alex [1 ]
Kennedyl, John [1 ]
Israeli, Ora [1 ]
机构：
[1] Rambam Hlth Care Campus, Haifa, Israel
来源：
JOURNAL OF NUCLEAR MEDICINE | 2017年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
668
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Pre- or Post-Chemotherapy: Effect of 177Lu-PSMA Radioligand Therapy on PSMA Expression
    Yadav, Surekha
    Heath, Courtney Lawhn
    Juarez, Roxanna
    De Kouchkovsky, Ivan
    Aggarwal, Rahul
    Hope, Thomas
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [22] 177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177Lu-PSMA-I&T Therapy
    John, Nikeith
    Pathmanandavel, Sarennya
    Crumbaker, Megan
    Counter, William
    Ho, Bao
    Yam, Andrew O.
    Wilson, Peter
    Niman, Remy
    Ayers, Maria
    Poole, Aron
    Hickey, Adam
    Agrawal, Shikha
    Perkins, Gary
    Kallinen, Annukka
    Eslick, Enid
    Stockler, Martin R.
    Joshua, Anthony M.
    Nguyen, Andrew
    Emmett, Louise
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (03) : 410 - 415
  • [23] Single-Time-Point Dosimetry of 177Lu-PSMA-617 Radionuclide Therapy with SPECT/CT
    Burkerr, Brian J.
    RADIOLOGY-IMAGING CANCER, 2023, 5 (02):
  • [24] An Assessment of the Accuracy of Quantitative SPECT/CT Imaging Using Tc99m and Lu177
    Johnson, J.
    Adamson, K.
    Alkahtani, T.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S254 - S255
  • [25] Lu177 Radioligand therapy: Potential for Modifying Administered Activity to Maximize the Probability of Complication Free Tumor Control
    Mikell, J.
    Fitzpatrick, K.
    Altman, M. B.
    Dewaraja, Y. K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S165 - S165
  • [26] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response Reply
    Yadav, Madhav Prasad
    Ballal, Sanjana
    Tripathi, Madhavi
    Bal, Chandrasekhal
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (01) : 168 - 169
  • [27] 177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?
    Kambiz Rahbar
    Hojjat Ahmadzadehfar
    Martin Boegemann
    European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45 : 513 - 514
  • [28] Experimental 177Lu-PSMA-617 radioligand therapy in a patient with extended metastasized leiomyosarcoma
    Jueptner, Michael
    Marx, Marlies
    Zuhayra, Maaz
    Luetzen, Ulf
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2019, 58 (04): : 328 - 330
  • [29] 177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?
    Rahbar, Kambiz
    Ahmadzadehfar, Hojjat
    Boegemann, Martin
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (03) : 513 - 514
  • [30] Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
    Kratochwil, Clemens
    Fendler, Wolfgang P.
    Eiber, Matthias
    Hofman, Michael S.
    Emmett, Louise
    Calais, Jeremie
    Osborne, Joseph R.
    Iravani, Amir
    Koo, Phillip
    Lindenberg, Liza
    Baum, Richard P.
    Bozkurt, Murat Fani
    Bolton, Roberto Delgado C.
    Ezziddin, Samer
    Forrer, Flavio
    Hicks, Rodney J.
    Hope, Thomas A.
    Kabasakal, Levent
    Konijnenberg, Mark
    Kopka, Klaus
    Lassmann, Michael
    Mottaghy, Felix M.
    Oyen, Wim J. G.
    Rahbar, Kambiz
    Schoder, Heiko
    Virgolini, Irene
    Bodei, Lisa
    Fanti, Stefano
    Haberkorn, Uwe
    Hermann, Ken
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (09) : 2830 - 2845
12345